These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

845 related items for PubMed ID: 21685535

  • 1. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
    Ueda Y, Marusawa H, Egawa H, Okamoto S, Ogura Y, Oike F, Nishijima N, Takada Y, Uemoto S, Chiba T.
    Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
    [Abstract] [Full Text] [Related]

  • 2. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B, Roque-Afonso AM, Sebagh M, Delvart V, Duclos-Vallee JC, Castaing D, Samuel D.
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [Abstract] [Full Text] [Related]

  • 3. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, Chang MH, Lee PH.
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [Abstract] [Full Text] [Related]

  • 4. De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.
    Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Zhu JJ, Wang SY, Qiu DK.
    J Dig Dis; 2013 Aug; 14(8):439-45. PubMed ID: 23638710
    [Abstract] [Full Text] [Related]

  • 5. Reactivation of hepatitis B virus with mutated hepatitis B surface antigen in a liver transplant recipient receiving a graft from an antibody to hepatitis B surface antigen- and antibody to hepatitis B core antigen-positive donor.
    Blaich A, Manz M, Dumoulin A, Schüttler CG, Hirsch HH, Gerlich WH, Frei R.
    Transfusion; 2012 Sep; 52(9):1999-2006. PubMed ID: 22313146
    [Abstract] [Full Text] [Related]

  • 6. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.
    Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, Gigou M, Shouval D, Dussaix E.
    Gut; 2002 Jan; 50(1):95-9. PubMed ID: 11772974
    [Abstract] [Full Text] [Related]

  • 7. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
    Wadhawan M, Gupta S, Goyal N, Taneja S, Kumar A.
    Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
    [Abstract] [Full Text] [Related]

  • 8. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
    Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, Guarrera JV, Emond JC, Brown RS.
    Transplantation; 2013 Apr 15; 95(7):960-5. PubMed ID: 23545507
    [Abstract] [Full Text] [Related]

  • 9. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
    Prieto M, Gómez MD, Berenguer M, Córdoba J, Rayón JM, Pastor M, García-Herola A, Nicolás D, Carrasco D, Orbis JF, Mir J, Berenguer J.
    Liver Transpl; 2001 Jan 15; 7(1):51-8. PubMed ID: 11150423
    [Abstract] [Full Text] [Related]

  • 10. Clinical course of de novo hepatitis B infection after pediatric liver transplantation.
    Su WJ, Ho MC, Ni YH, Wu JF, Jeng YM, Chen HL, Wu YM, Hu RH, Chang MH, Lee PH.
    Liver Transpl; 2010 Feb 15; 16(2):215-21. PubMed ID: 20104496
    [Abstract] [Full Text] [Related]

  • 11. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A.
    Biol Blood Marrow Transplant; 2010 Jun 15; 16(6):809-17. PubMed ID: 20060484
    [Abstract] [Full Text] [Related]

  • 12. De novo and apparent de novo hepatitis B virus infection after liver transplantation.
    Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, David MF, Arulnaden JL, Bismuth A, Reynes M, Bismuth H.
    J Hepatol; 1997 Mar 15; 26(3):517-26. PubMed ID: 9075658
    [Abstract] [Full Text] [Related]

  • 13. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I, Baiocchi L, Tariciotti L, Di Paolo D, Milana M, Santopaolo F, Manzia TM, Toti L, Svicher V, Tisone G, Perno CF, Angelico M.
    Liver Transpl; 2016 Sep 15; 22(9):1205-13. PubMed ID: 27272189
    [Abstract] [Full Text] [Related]

  • 14. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.
    Rosenau J, Kreutz T, Kujawa M, Bahr MJ, Rifai K, Hooman N, Finger A, Michel G, Nashan B, Kuse ER, Klempnauer J, Tillmann HL, Manns MP.
    J Hepatol; 2007 Apr 15; 46(4):635-44. PubMed ID: 17316869
    [Abstract] [Full Text] [Related]

  • 15. Risks and treatment strategies for de novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.
    Dong C, Gao W, Ma N, Sun C, Zheng WP, Wang K, Shen ZY.
    Pediatr Transplant; 2017 Mar 15; 21(2):. PubMed ID: 27933716
    [Abstract] [Full Text] [Related]

  • 16. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen.
    Cooreman MP, Leroux-Roels G, Paulij WP.
    J Biomed Sci; 2001 Mar 15; 8(3):237-47. PubMed ID: 11385295
    [Abstract] [Full Text] [Related]

  • 17. Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination.
    Lai MW, Lin TY, Tsao KC, Huang CG, Hsiao MJ, Liang KH, Yeh CT.
    Gastroenterology; 2012 Aug 15; 143(2):400-7. PubMed ID: 22580098
    [Abstract] [Full Text] [Related]

  • 18. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors.
    Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, Jawan B, Chiu KW, Chen CL.
    Clin Transplant; 2002 Dec 15; 16(6):405-9. PubMed ID: 12437618
    [Abstract] [Full Text] [Related]

  • 19. Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft.
    Wang SH, Loh PY, Lin TL, Lin LM, Li WF, Lin YH, Lin CC, Chen CL.
    Liver Transpl; 2017 Oct 15; 23(10):1266-1272. PubMed ID: 28691231
    [Abstract] [Full Text] [Related]

  • 20. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
    Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, Hashimoto K, Mochida Y, Maehara Y, Kuwano H.
    Liver Int; 2005 Dec 15; 25(6):1169-74. PubMed ID: 16343068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.